http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108976235-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2018-09-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-09-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2019-09-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-108976235-B |
| titleOfInvention | A kind of quianzolinones and application thereof |
| abstract | This application discloses be related to having quianzolinones and its pharmaceutically acceptable salt, hydrate or prodrug shown in general formula I in technical field of organic chemistry.Wherein, substituent R 1, R2 have the meaning provided in the description.The invention further relates to general formula I Compound and its pharmaceutically acceptable salt, hydrate or prodrug treating the purposes in drug due to IDO kinases overexpression diseases caused, the especially purposes in the drug of preparation treatment and/or pre- anti-cancer. |
| priorityDate | 2018-09-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 97.